alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2023112EN.01001101.xml

| 27.3.2023 | EN | Official Journal of the European Union | C 112/11 |
| --- | --- | --- | --- |

27.3.2023

EN

Official Journal of the European Union

C 112/11

---

Judgment of the Court (Tenth Chamber) of 9 February 2023 (request for a preliminary ruling from the Tribunale Amministrativo Regionale per la Lombardia — Italy) — VZ v CA

(Case C-53/22, (1) VZ (Tenderer definitively excluded))

(Reference for a preliminary ruling - Review procedures in respect of the award of public supply and public works contracts - Directive 89/665/EEC - Article 1(3) - Interest in bringing proceedings - Access to the review procedures - Grave professional misconduct on account of an anticompetitive agreement - Other operator definitively excluded from participating in the procurement procedure concerned due to failure to meet the minimum requirements)

(2023/C 112/14)

Language of the case: Italian

Referring court

Tribunale Amministrativo Regionale per la Lombardia

Parties to the main proceedings

Applicant: VZ

Defendant: CA

Intervening parties: RT, BO, Regione Lombardia, Regione Liguria

Operative part of the judgment

Article 1(3) of Council Directive 89/665/EEC of 21 December 1989 on the coordination of the laws, regulations and administrative provisions relating to the application of review procedures to the award of public supply and public works contracts, as amended by Directive 2014/23/EU of the European Parliament and of the Council of 26 February 2014

must be interpreted as not precluding legislation of a Member State which does not allow an operator which is prevented from participating in a procedure for the award of a public contract on the ground that it did not satisfy one of the conditions for participation laid down in the call for tenders concerned, and whose action against the inclusion of that condition in that call for tenders was rejected by a decision which acquired the force of res judicata, to challenge the refusal of the contracting authority concerned to annul the decision awarding that public contract following confirmation by a court decision that the successful tenderer and all the other tenderers had participated in an agreement constituting an infringement of the competition rules in the same sector as that concerned by the procedure for the award of that public contract.

---

(1)  OJ C 148, 4.4.2022.

---
EX-10.22





 Certain identified information has been excluded from this exhibit because it is both not material and
is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

 
 Exhibit 10.22 

AMENDMENT 
 TO THE 

EXCLUSIVE LICENSE 
 BETWEEN 

CARIBOU BIOSCIENCES, INC. 
 AND

 THE UNIVERSITY OF VIENNA 

AND 
 THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA 
 FOR 

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION 

AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION 












 Amendment Agreement 

Caribou Biosciences , Inc. (“Caribou”), the University of Vienna (“University of Vienna”) and the Regents of the University of California
(“Regents”) do hereby agree to amend the EXCLUSIVE LICENSE BETWEEN CARIBOU BIOSCIENCES, INC., THE UNIVERSITY OF VIENNA AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA relating to [***] (“Agreement”) in the respects shown below
(“Amendment Agreement”): 
  

	1.	 Section 1.7 of the Agreement shall be deleted and replaced with the following: 



1.7 HHMI assigned its rights in the Inventions to REGENTS [***] and accordingly, REGENTS has the authority to negotiate a license on behalf of UNIVERSITY OF
VIENNA in the Invention and any patent rights claiming it. REGENTS have no authority to license Emmanuelle Charpentier’s interest or rights in the Inventions. 
  

	2.	 Article 17 of the Agreement shall be deleted and replaced with the following: 



17. ASSIGNMENT 
 [***] 

[signature page to follow] 












 IN WITNESS WHEREOF, the parties hereto executed this Amendment Agreement by their duly authorized
officers or representatives. 
  

									
	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	 		 	CARIBOU BIOSCIENCES, INC.
					
	By:	 	 /s/ Michael Katz
	 		 	By:	 	 /s/ Rachel E. Haurwitz

	Michael Katz	 		 	Rachel E. Haurwitz
	Executive Director	 		 	President
	Intellectual Property and Industry Research Alliances	 		 	
					
	Date:	 	 April 9, 2013
	 		 	Date:	 	 April 17, 2013

				
	THE UNIVERSITY OF VIENNA	 		 		 	
					
	By:	 	 /s/ Susanne Weigelin-Schwiedrzik
	 		 		 	
	Susanne Weigelin-Schwiedrzik	 		 		 	
	Vice-Rector for Research and Career Development	 		 		 	
					
	DATE	 	 April 16, 2013
	 		 		 	


  
 -3-
# C_2022284EN.01004601.xml

| 25.7.2022 | EN | Official Journal of the European Union | C 284/46 |
| --- | --- | --- | --- |

25.7.2022

EN

Official Journal of the European Union

C 284/46

---

Action brought on 17 May 2022 — Biogen Netherlands v Commission

(Case T-279/22)

(2022/C 284/63)

Language of the case: English

Parties

Applicant: Biogen Netherlands BV (Badhoevedorp, Netherlands) (represented by: C. Schoonderbeek, lawyer)

Defendant: European Commission

Form of order sought

The applicant claims that the Court should:

| — | annul the decision of the European Commission of 13 May 2022 C(2022) 3252 (final) granting marketing authorisation under Regulation (EC) No 726/2004 (1) for ‘Dimethyl fumarate Mylan — dimethyl fumarate’, a medicinal product for human use; and |
| --- | --- |

—

annul the decision of the European Commission of 13 May 2022 C(2022) 3252 (final) granting marketing authorisation under Regulation (EC) No 726/2004 (1) for ‘Dimethyl fumarate Mylan — dimethyl fumarate’, a medicinal product for human use; and

| — | order the Commission to pay the costs. |
| --- | --- |

—

order the Commission to pay the costs.

Pleas in law and main arguments

In support of the action, the applicant relies on two pleas in law.

| 1. | First plea in law, alleging failure to observe the system of Directive 2001/83/EC (2) in relation to the rules on regulatory data protection, including Article 6(1) of that Directive, and the obligations of generic applicants under Article 10(1) of that Directive. |
| --- | --- |

1.

First plea in law, alleging failure to observe the system of Directive 2001/83/EC (2) in relation to the rules on regulatory data protection, including Article 6(1) of that Directive, and the obligations of generic applicants under Article 10(1) of that Directive.

| 2. | Second plea in law, alleging failure to recognise the consequences of the Opinion of the Committee for Medicinal Products for Human Use of 11 November 2021 for the question whether the marketing authorisation for the medicinal product Fumaderm was capable of commencing a global marketing authorisation for the medicinal product Tecfidera in accordance with Article 6(1), second subparagraph, of Directive 2001/83/EC. |
| --- | --- |

2.

Second plea in law, alleging failure to recognise the consequences of the Opinion of the Committee for Medicinal Products for Human Use of 11 November 2021 for the question whether the marketing authorisation for the medicinal product Fumaderm was capable of commencing a global marketing authorisation for the medicinal product Tecfidera in accordance with Article 6(1), second subparagraph, of Directive 2001/83/EC.

---

(1)  Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004, L 136, p. 1).

(2)  Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001, L 311, p. 67).

---
EXHIBIT 32.1



CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of Bitstream Inc. (the
Company) on Form 10-Q for the quarterly period ended March 31, 2004 as filed with the Securities and Exchange Commission on the date hereof (the Report), each of the undersigned, in the capacities and on the dates indicated
below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his or her knowledge:



| | 1. | The Report complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | -- | ---------------------------------------------------------------------------------------------------------------



| | 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.
| | -- | ---------------------------------------------------------------------------------------------------------------------------------------------------



|                                   |  |                                            |  |             
|---------------------------------- |  | ------------------------------------------ |  | ------------
|SIGNATURE                          |  | TITLE                                      |  | DATE        
|/s/ Anna M. ChagnonAnna M. Chagnon |  | President and Chief Executive Officer      |  | May 17, 2004
|                                   |  |                                           
|/s/ James P. DoreJames P. Dore     |  | Vice President and Chief Financial Officer |  | May 17, 2004



This certification
accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under
that section. This certification shall not be deemed incorporated by reference in any filing under the Securities Act or Exchange Act, except to the extent that the Company specifically incorporates it by reference.



A signed original of this written statement required by Section 906, or other
document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form with the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the
Company and furnished to the Securities and Exchange Commission or its staff upon request.
No. 11-11034.

#### Hunter *v.*Louisiana.

Ct. App. La., 2d Cir. Certiorari denied.
# C_2021401EN.01001901.xml

| 4.10.2021 | EN | Official Journal of the European Union | C 401/19 |
| --- | --- | --- | --- |

4.10.2021

EN

Official Journal of the European Union

C 401/19

---

Action brought on 16 August 2021 — Tinnus Enterprises v EUIPO — Mystic Products Import & Export (Fluid distribution equipment)

(Case T-505/21)

(2021/C 401/20)

Language of the case: English

Parties

Applicant: Tinnus Enterprises LLC (Plano, Texas, United States) (represented by: T. Wuttke, lawyer)

Defendant: European Union Intellectual Property Office (EUIPO)

Other party to the proceedings before the Board of Appeal: Mystic Products Import & Export, SL (Badalona, Spain)

Details of the proceedings before EUIPO

Proprietor of the design at issue: Applicant before the General Court

Design at issue: Community design No 1 431 829-0010

Contested decision: Decision of the Third Board of Appeal of EUIPO of 9 June 2021 in Case R 1003/2018-3

Form of order sought

The applicant claims that the Court should:

| — | annul the contested decision; |
| --- | --- |

—

annul the contested decision;

| — | alter the contested decision to:






  — | allow the applicant’s appeal, |
| --- | --- | --- |

—

alter the contested decision to:

—

allow the applicant’s appeal,

| — | dismiss in its entirety the invalidity applicant’s application ICD 10 296 to declare the contested design invalid, |
| --- | --- |

—

dismiss in its entirety the invalidity applicant’s application ICD 10 296 to declare the contested design invalid,

| — | order the invalidity applicant to pay the applicant’s costs in front of the Board of Appeal and the Invalidity Division; |
| --- | --- |

—

order the invalidity applicant to pay the applicant’s costs in front of the Board of Appeal and the Invalidity Division;

| — | order the invalidity applicant to pay the applicant’s fees and costs. |
| --- | --- |

—

order the invalidity applicant to pay the applicant’s fees and costs.

Pleas in law

| — | Infringement of the principles set forth in the judgment of 24 March 2021, Lego v EUIPO — Delta Sport Handelskontor (Building block from a toy building set) (T-515/19, not published, EU:T:2021:155); |
| --- | --- |

—

Infringement of the principles set forth in the judgment of 24 March 2021, Lego v EUIPO — Delta Sport Handelskontor (Building block from a toy building set) (T-515/19, not published, EU:T:2021:155);

| — | Infringement of the principles set forth in the judgment of 8 March 2018, DOCERAM (C-395/16, EU:C:2018:172); |
| --- | --- |

—

Infringement of the principles set forth in the judgment of 8 March 2018, DOCERAM (C-395/16, EU:C:2018:172);

| — | Infringement of Article 8(1) of Council Regulation (EC) No 6/2002; |
| --- | --- |

—

Infringement of Article 8(1) of Council Regulation (EC) No 6/2002;

| — | Misinterpretation of patent application EP 3 005 948 A2 and the applicant’s multiple design application No. 1 431 829-0001-0010. |
| --- | --- |

—

Misinterpretation of patent application EP 3 005 948 A2 and the applicant’s multiple design application No. 1 431 829-0001-0010.

---
116TH CONGRESS 

1ST SESSION H. R. 95 

AN ACT 

To amend title 38, United States Code, to ensure that children of homeless veterans are included in the calculation 

of the amounts of certain per diem grants. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 
2 

•HR 95 EH

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Homeless Veteran 

3 Families Act’’. 

4 SEC. 2. MODIFICATION OF CALCULATION OF AMOUNTS OF 

5 PER DIEM GRANTS. 

6 Section 2012(a)(2)(B) of title 38, United States 

7 Code, is amended— 

8 (1) in clause (i), by inserting ‘‘or (iii)’’ after 

9 ‘‘clause (ii)’’; and 

10 (2) by adding at the end the following new 

11 clause: 

12 ‘‘(iii) With respect to a homeless veteran who 

13 has care of a minor dependent while receiving serv14 ices from the grant recipient or eligible entity, the 

15 daily cost of care shall be the sum of the daily cost 

16 of care determined under subparagraph (A) plus, for 

17 each such minor dependent, an amount that equals 

18 50 percent of such daily cost of care.’’. 

Passed the House of Representatives October 15, 

2019. 

Attest: 

Clerk. 

116TH CONGRESS 

1ST SESSION H. R. 95 

AN ACT 

To amend title 38, United States Code, to ensure 

diem grants. the calculation of the amounts of certain per that children of homeless veterans are included in
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          MAY-31-1997
<PERIOD-START>                             JUN-01-1996
<PERIOD-END>                               NOV-30-1996
<CASH>                                         598,563
<SECURITIES>                                         0
<RECEIVABLES>                                2,919,065
<ALLOWANCES>                                    59,753
<INVENTORY>                                  2,005,827
<CURRENT-ASSETS>                             5,707,178
<PP&E>                                       2,496,546
<DEPRECIATION>                               2,165,104
<TOTAL-ASSETS>                               8,454,481
<CURRENT-LIABILITIES>                        2,615,089
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        45,541
<OTHER-SE>                                   5,729,066
<TOTAL-LIABILITY-AND-EQUITY>                 8,454,481
<SALES>                                      5,449,181
<TOTAL-REVENUES>                             6,111,872
<CGS>                                        3,939,178
<TOTAL-COSTS>                                4,319,316
<OTHER-EXPENSES>                             1,551,180
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               7,767
<INCOME-PRETAX>                                233,609
<INCOME-TAX>                                   108,004
<INCOME-CONTINUING>                            125,605
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   125,605
<EPS-PRIMARY>                                      .03
<EPS-DILUTED>                                        0
        

</TABLE>
<PAGE>
 
                                                                     EXHIBIT 8.1

                                                                    July 8, 1997

00116.0393                           

Houston Industries Incorporated
Houston Industries Plaza
1111 Louisiana Street
Houston, Texas 77002

Ladies and Gentlemen:

        We have acted as counsel for Houston Industries Incorporated, a Texas 
corporation (the "Company"), in connection with the Registration Statement on 
Form S-3 (the "Registration Statement"), including a prospectus (the 
"Prospectus"), filed by the Company with the Securities and Exchange Commission 
under the Securities Act of 1933, as amended, relating to the proposed issuance
and sale of up to 22,909,040 ___% Automatic Common Exchange Securities (the
"Securities"). The Securities will be issued under an Indenture (the
"Indenture") between the Company and The First National Bank of Chicago, as
Trustee.
        We have examined the Prospectus and such other documents and corporate 
records as we have deemed necessary or appropriate for purposes of this opinion.
In addition, we have assumed that the Securities will be issued in accordance 
with the Indenture and the other operative documents described in the 
Prospectus.

        Based on certain assumptions set forth therein, statements of legal 
conclusion set forth under the heading "Risk Factors--Uncertainty of Federal 
Income Tax Consequences" and under the heading "Certain United States Federal 
Income Tax Considerations" in the Prospectus reflect our opinions on the 
material United States federal income tax consequences of the purchase, 
ownership and disposition of the Securities based on the Internal Revenue Code 
of 1986 and applicable regulations thereunder, both as in effect on the date 
hereof, and on reported judicial decisions, although, as stated in the 
Prospectus, no existing statutory, judicial or administrative authority 
directly addresses the characterization of the Securities for U.S. federal 
income tax purposes and therefore there exists significant uncertainty 
concerning the proper tax treatment of the Securities.

        Our opinion is limited to tax matters specifically covered hereby.
<PAGE>
 
Houston Industries Incorporated       -2-                         July 8, 1997



        We hereby consent to the filing of this opinion as Exhibit 8 to the 
Registration Statement and to the references to this Firm in the sections 
captioned "Certain United States Federal Income Tax Considerations" and 
"Validity of the Securities" in the Prospectus. In giving this consent, we do 
not thereby admit that we come within the category of a person whose consent is 
required under Section 7 of the Securities Act of 1933, as amended, or the rules
and regulations of the Securities and Exchange Commission thereunder.

                                       Very truly yours,

                                       BAKER & BOTTS, L.L.P. 

GVN: 430
EXHIBIT 32.2
                                                                    ------------

                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350


         Pursuant to 18 U.S.C. ss. 1350, the undersigned officer of Harold's
Stores, Inc. (the "Company"), hereby certifies that the Company's Quarterly
Report on Form 10-Q for the quarter ended July 29, 2006 (the "Report") fully
complies with the requirements of Section 13(a) or 15(d), as applicable, of the
Securities Exchange Act of 1934 and that the information contained in the Report
fairly presents, in all material respects, the financial condition and results
of operations of the Company.

Date: September 12, 2006                           /s/ Jodi Taylor
                                                   -------------------------
                                                   Jodi Taylor
                                                   Chief Financial Officer
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                          18,529
<SECURITIES>                                     2,557
<RECEIVABLES>                                   23,431
<ALLOWANCES>                                     1,910
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                         443,167
<DEPRECIATION>                                 226,741
<TOTAL-ASSETS>                                 281,605
<CURRENT-LIABILITIES>                                0
<BONDS>                                        337,784
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                   (108,246)
<TOTAL-LIABILITY-AND-EQUITY>                   281,605
<SALES>                                              0
<TOTAL-REVENUES>                                83,896
<CGS>                                                0
<TOTAL-COSTS>                                   49,172
<OTHER-EXPENSES>                                 7,726
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              25,552
<INCOME-PRETAX>                                  5,293
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                              5,293
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     5,293
<EPS-PRIMARY>                                      .82
<EPS-DILUTED>                                      .82
        

</TABLE>